Capital Research Global Investors Grows Stake in Amgen Inc. $AMGN

Capital Research Global Investors boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 2.7% during the 3rd quarter, Holdings Channel.com reports. The firm owned 4,731,290 shares of the medical research company’s stock after buying an additional 122,631 shares during the quarter. Capital Research Global Investors’ holdings in Amgen were worth $1,335,168,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently modified their holdings of the business. Evelyn Partners Investment Management LLP bought a new stake in shares of Amgen during the second quarter valued at approximately $32,000. Howard Hughes Medical Institute acquired a new position in shares of Amgen in the 2nd quarter valued at $32,000. Cloud Capital Management LLC acquired a new stake in shares of Amgen during the third quarter worth about $34,000. AXS Investments LLC acquired a new stake in Amgen during the 3rd quarter worth about $42,000. Finally, Winnow Wealth LLC acquired a new position in Amgen in the third quarter valued at approximately $47,000. Institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. HSBC restated a “buy” rating and set a $425.00 price objective on shares of Amgen in a research report on Wednesday, December 10th. Piper Sandler lifted their target price on shares of Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Royal Bank Of Canada lifted their target price on Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a research report on Wednesday, February 4th. Scotiabank began coverage on shares of Amgen in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $385.00 price target on the stock. Finally, The Goldman Sachs Group boosted their price objective on Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Amgen presently has an average rating of “Hold” and an average target price of $354.17.

Amgen Stock Up 2.0%

AMGN opened at $376.97 on Tuesday. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The business’s fifty day moving average is $354.21 and its two-hundred day moving average is $323.38. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The company has a market cap of $203.21 billion, a price-to-earnings ratio of 26.49, a PEG ratio of 3.67 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same period in the previous year, the firm posted $5.31 earnings per share. The business’s revenue for the quarter was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Friday, May 15th. Amgen’s payout ratio is 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.